LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Escalon Acquires About 94% of Drew Scientific

By Labmedica staff writers
Posted on 06 Oct 2004
The acquisition of approximately 93.7% of the ordinary shares outstanding of Drew Scientific Group plc (Cumbria, UK) has been announced by Escalon Medical Corp. (Wayne, PA, USA). Escalon states that its revised purchase offer is now closed. The company intends to use the procedure established under United Kingdom law to compulsorily acquire any remaining shares of Drew.

Drew Scientific, although UK-based, has additional manufacturing operations in Texas and Connecticut (both in the USA). This diagnostics company specializes in the design, manufacture, sale, and distribution of analytic systems for laboratory testing worldwide. Drew provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases, and hematology, as well as veterinary hematology and blood chemistry

Escalon markets and distributes ophthalmic diagnostics, surgical and pharmaceutical products as well as vascular access devices. The company seeks to further diversity its product line to achieve critical mass in sales and take better advantages of its distribution capabilities through internal product development, acquisitions, or strategic partnerships.



Related Links:
Drew Scientific
Escalon

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer

Latest Industry News

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
06 Oct 2004  |   Industry

Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
06 Oct 2004  |   Industry

New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
06 Oct 2004  |   Industry